Piper Jaffray analyst Joshua Schimmer was out pounding the table on GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH), reiterating an Overweight rating with a price target of $147, which represents a potential upside of 29% from where the stock is currently trading.
Schimmer wrote, “As we pass the midway point of 2015, we’re refreshing our thinking on our coverage universe. For GWPH, this will be a defining year, as the P3 data for Epidiolex in Dravet Syndrome and Lennox Gastaut will shape future prospects for the company. Based on the strong (albeit open label) P2 data along with countless supportive anecdotes in the media and from specialists who have been able to access either Epidiolex in the expanded access program or through medical marijuana dispensaries, we are confident in prospects for success.”
The analyst continued, “The refractory seizure indication is one of the few Orphan/NonOrphan indications (discussed below) and represents a sizable commercial opportunity for GWPH. We reiterate our OW rating as GWPH remains a top mid-cap pick for us for the duration of the year.””
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Joshua Schimmer has a total average return of 11.4% and a 59.9% success rate. Schimmer has a 36.8% average return when recommending GWPH, and is ranked #274 out of 3721 analysts.
All the 4 analysts polled by TipRanks rate GW Pharmaceuticals stock a Buy. With a return potential of 10%, the stock’s consensus target price stands at $125.67.